Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 23 August 2016, 18:09 HKT/SGT
Share:
    

Source: Eisai
Eisai to Launch Chocola BB Mouth Ulcer Repair Shot

TOKYO, Aug 23, 2016 - (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch "Chocola BB Mouth Ulcer Repair Shot"(Third-class OTC drug) for mouth ulcers in Japan on Thursday, August 25. The product is the first oral care spray to be marketed under the Chocola BB brand.

Mouth ulcer is a general term that refers to any inflammation of the mucous membrane in the mouth. In many cases, it is thought that nutritional imbalances, lifestyle changes and/or stress lead to a decrease in the mucous membrane's ability to regenerate, allowing bacteria to penetrate the membrane and cause an ulcer to form.

Chocola BB Mouth Ulcer Repair Shot is a medicated spray that is effective for mouth ulcers and soothing pain caused by inflammation in the throat. Containing antiseptic cetylpyridinium chloride (CPC) that keeps the mouth clean, as well as azulene which acts to repair the mucous membrane, the spray alleviates the symptoms of mouth ulcers by allowing the active ingredients to be directly applied into the mouth. It also comes in a compact form making it portable and easy to use anywhere without having to directly touch the affected area.

Centered around the signature OTC product Chocola BB Plus (Third-class OTC drug) for the relief of skin trouble, acne and mouth ulcers, Eisai has been expanding the Chocola BB brand to suit the needs and lifestyles of its customers such as Chocola BB Royal 2 (quasi-drug), a nutritional drink for invigoration when physically fatigued, and Chocola BB Joma, a soft drink that contains vitamin B6 (Food with Nutrient Function Claims).

Through the Chocola BB brand, Eisai will continue to respond to the diverse needs of female consumers and support an ever-growing number of people to achieve health and beauty in their everyday lives.

Product Outline

1. Product Name:

Chocola BB Mouth Ulcer Repair Shot (Third-class OTC Drug, oral throat medicine)

2. Active Ingredients (per 100 ml):

Azulene sulfonate sodium hydrate 20 mg
Cetylpyridinium chloride hydrate 300 mg

3. Indications:

Mouth ulcers, and alleviation of pain, swelling, roughness, discomfort, hoarseness caused by inflammation in the throat

4. Dosage:

Spray on the affected part several times a day

5. Manufacturer's Suggested Retail Price (excluding tax):

980 yen per bottle (30 ml)

6. Manufactured By:

Fukuchi Pharmaceutical Co., Ltd.

7. Marketed By:

Eisai Co., Ltd.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120



Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Feb 20, 2025 12:29 HKT/SGT
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
Feb 14, 2025 11:09 HKT/SGT
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease
Feb 3, 2025 16:23 HKT/SGT
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
Jan 28, 2025 08:46 HKT/SGT
FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jan 22, 2025 16:18 HKT/SGT
Eisai Listed as a Global 100 Most Sustainable Corporation for The Ninth Time Highest Ranked Global Pharmaceutical Company
Jan 15, 2025 09:03 HKT/SGT
FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jan 7, 2025 08:14 HKT/SGT
Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer's Disease
Dec 23, 2024 16:22 HKT/SGT
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
Dec 11, 2024 13:45 HKT/SGT
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
Dec 5, 2024 10:22 HKT/SGT
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: